![]()
Pfizer’s Cardiovascular and Metabolic Diseases Research Unit (CVMED RU) has relocated to Cambridge, Massachusetts, bringing our outstanding drug discovery scientists to the heart of one of the leading global centers for biomedical research into cardiovascular and metabolic diseases.
Pfizer’s Cardiovascular and Metabolic Diseases Research Unit is dedicated to developing innovative medicines to slow disease progression and improve the quality of life of patients with type 2 diabetes and cardiovascular disease.